Cynata Therapeutics Limited (CYYNF)
- PR Newswire
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
- PR Newswire
First Patient Treated in Phase 2 GvHD Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
- PR Newswire
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU), up to the 10-week follow-up time point.
